enGene (NASDAQ:ENGN – Get Free Report) is one of 439 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare enGene to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Volatility & Risk
enGene has a beta of -0.63, meaning that its share price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 1.21, meaning that their average share price is 21% more volatile than the S&P 500.
Institutional & Insider Ownership
64.2% of enGene shares are held by institutional investors. Comparatively, 30.7% of shares of all “Biotechnology” companies are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 22.6% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Dividends
Analyst Recommendations
This is a summary of current recommendations and price targets for enGene and its competitors, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 734 | 2347 | 5545 | 66 | 2.57 |
enGene presently has a consensus price target of $34.40, suggesting a potential upside of 531.19%. As a group, “Biotechnology” companies have a potential upside of 15.97%. Given enGene’s stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than its competitors.
Profitability
This table compares enGene and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | -63.25% | -5.65% |
enGene Competitors | -11,893.41% | -127.11% | -24.51% |
Earnings and Valuation
This table compares enGene and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $104.74 million | -3.34 |
enGene Competitors | $156.02 million | -$17.55 million | 80.99 |
enGene’s competitors have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
enGene beats its competitors on 10 of the 15 factors compared.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.